PFIZER INC (PFE) Stock News

Why Pfizer (PFE) Outpaced the Stock Market Today

In the most recent trading session, Pfizer (PFE) closed at $26.64, indicating a +1.29% shift from the previous trading day.

Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants

Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits.

Pfizer Unusual Options Activity For January 21

Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever

3 Subtle Investing Mistakes I Won't Repeat in 2025 And Beyond

Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.

What's going on in today's session: S&P500 most active stocks

Let's have a look at the most active S&P500 stocks in today's session.

Why Pfizer sold its $3 billion stake in Haleon

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core pharmaceutical operations.

Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A. Cohen's former hedge fund, SAC Capital Management. The money was left over from SAC's $602 million settlement in March 2013 with the U.S. Securities and Exchange Commission over trades in drugmakers Wyeth and Elan by Mathew Martoma, who worked at an SAC unit and was later convicted. Pfizer said it deserved the $75.2 million because a neurologist who tipped Martoma about a 2008 Alzheimer's drug trial owed a fiduciary duty to Wyeth, which Pfizer bought in 2009, because he had been a consultant there.

Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner

Pfizer intends to sell about 700 million ordinary shares in Haleon, cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.

Pfizer Offers to Sell 700 Million More Shares of Haleon

Pfizer Inc. is offering around 700 million shares in Haleon Plc, representing a roughly 7.7% stake in the maker of Sensodyne tooth paste.

Pfizer Offers to Sell 700 Million More Shares of Haleon

(Bloomberg) -- Pfizer Inc. is offering around 700 million shares in Haleon Plc, representing a roughly 7.7% stake in the maker of Sensodyne tooth paste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyA Blueprint for Better Bike LanesAs E-Bikes Boom in NYC, Some Call for More RegulationsThe deal could raise around £2.6 billion ($3.1 billion) for the seller, which is offering the shares through an accelerated placement with investors, according to terms seen by Bl

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?

Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.

Pfizer CEO Says Activist Wants Minimal Changes, Plays Down Fight

Pfizer Inc.’s dispute with activist firm Starboard Value LP isn’t “an aggressive situation,” Chief Executive Officer Albert Bourla said, months after the feared investor disclosed a stake in the company and questioned his management.

Pfizer going 'all in' on obesity drug development, CEO Bourla says

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Exeuctive Officer Albert Bourla said at the JPMorgan Healthcare conference on Monday.

Moderna cuts sales forecast on weaker vaccine demand

Moderna shares slumped Monday on the companies downgraded 2025 outlook

The race for the leading next-gen weight-loss drug is still on

Novo Nordisk, Eli Lilly, Pfizer, Amgen and more are all racing to develop stronger and more convenient weight-loss drugs

Pfizer must face lawsuit over diversity fellowship program, US court rules

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker. At the urging of the group Do No Harm, a 2-1 panel of the New York-based 2nd U.S. Circuit Court of Appeals revisted a decision it issued last year holding the organization lacked legal standing to challenge the drugmaker's program in court.

Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns

Explore established industry leaders with impressive dividend yields that are demonstrating the potential for growth and continued performance in 2025.

Stay informed about the most active stocks in the S&P500 index on Monday's session. Discover the stocks that are generating the highest trading volume and driving market activity.

Let's have a look at the most active S&P500 stocks in today's session.

Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity.

Most active S&P500 stocks in Thursday's session